Nabsys Presents Data Detailing OhmX™ Platform's Unique Advantages of Genome Mapping at American Society of Human Genetics (ASHG) 2025 Annual Meeting

Electronic genome mapping (EGM) detects and validates structural variants in cancer genomes with improved accuracy over existing platforms, including optical mapping technologies

PROVIDENCE, R.I., Oct. 17, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, today presented data detailing the OhmX^™ Platform's unique advantages of genome mapping at the American Society of Human Genetics (ASHG) Annual Meeting taking place on October 14-18, 2025, in Boston, MA.

New Nabsys data in a poster titled "Electronic Genome Mapping of Somatic Structural Variants" (Poster # 9031F) highlights the OhmX Platform's unique ability to reliably detect and validate cancer genomes, complex structural variants (SVs) that present challenges to existing research methods. EGM verified 420 of the 592 insertions and deletions greater than 300 bp. The technology also demonstrated the ability to verify somatic SVs from tumor-derived cell lines from 300 bp to several megabases.

"Cancer is a devastating disease distinguished by nearly infinite permutations of SVs in the human genome. The ability to quickly and accurately identify SVs with EGM represents a major advancement in the application of personalized medicine and a breakthrough in disease pathology," said John Thompson, Ph.D., Principal Application Scientist at Nabsys. "These data demonstrate how the use of electronic detection improves upon expensive optical imaging, which is restricted by the diffraction limit of light waves. We look forward to applying these learnings to labs worldwide as we work to advance the critically important field of cancer research." 

"The presentations at the ASHG meeting further validate the OhmX Platform as an optimal solution for high-resolution SV analysis, and we were pleased to share the latest improvements and integrations of cutting-edge technology with the genomic research community," said Barrett Bready, M.D., founder and CEO of Nabsys. "By addressing critical research gaps, we are working to fulfill the promise of genome mapping technology as a powerful, cost-effective, and scalable solution for all."

All presentations from the ASHG Meeting are available on the "Resources" section of the Company's website at www.nabsys.com/resources?category=Posters.

About Nabsys 2.0, LLC

The Nabsys 2.0, LLC ("Nabsys") mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis.

For more information, visit https://www.nabsys.com.

Media Contact

David Rosen
Argot Partners
[email protected]
646-461-6387

SOURCE Nabsys